Elevated serum chemokine CCL22 levels in first-episode psychosis: associations with symptoms, peripheral immune state and in vivo brain glial cell function.

Brain / diagnostic imaging Chemokine CCL22 / metabolism Humans Longitudinal Studies Neuroglia / metabolism Psychotic Disorders

Journal

Translational psychiatry
ISSN: 2158-3188
Titre abrégé: Transl Psychiatry
Pays: United States
ID NLM: 101562664

Informations de publication

Date de publication:
16 03 2020
Historique:
received: 21 01 2020
accepted: 03 03 2020
revised: 18 02 2020
entrez: 18 3 2020
pubmed: 18 3 2020
medline: 22 6 2021
Statut: epublish

Résumé

Several lines of research support immune system dysregulation in psychotic disorders. However, it remains unclear whether the immunological marker alterations are stable and how they associate with brain glial cell function. This longitudinal study aimed at investigating whether peripheral immune functions are altered in the early phases of psychotic disorders, whether the changes are associated with core symptoms, remission, brain glial cell function, and whether they persist in a one-year follow-up. Two independent cohorts comprising in total of 129 first-episode psychosis (FEP) patients and 130 controls were assessed at baseline and at the one-year follow-up. Serum cyto-/chemokines were measured using a 38-plex Luminex assay. The FEP patients showed a marked increase in chemokine CCL22 levels both at baseline (p < 0.0001; Cohen's d = 0.70) and at the 12-month follow-up (p = 0.0007) compared to controls. The group difference remained significant (p = 0.0019) after accounting for relevant covariates including BMI, smoking, and antipsychotic medication. Elevated serum CCL22 levels were significantly associated with hallucinations (ρ = 0.20) and disorganization (ρ = 0.23), and with worse verbal performance (ρ = -0.23). Brain glial cell activity was indexed with positron emission tomography and the translocator protein radiotracer [

Identifiants

DOI: 10.1038/s41398-020-0776-z PMID: 32179746 PMC: PMC7075957
pubmed: 32179746
doi: 10.1038/s41398-020-0776-z
pii: 10.1038/s41398-020-0776-z
pmc: PMC7075957
doi:

Substances chimiques

CCL22 protein, human 0
Chemokine CCL22 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

94

Subventions

Organisme : Academy of Finland (Suomen Akatemia)
ID : 278155
Pays : International
Organisme : Academy of Finland (Suomen Akatemia)
ID : 278181
Pays : International
Organisme : Academy of Finland (Suomen Akatemia)
ID : 323035
Pays : International

Références

Goldsmith, D. R., Rapaport, M. H. & Miller, B. J. A meta-analysis of blood cytokine network alterations in psychiatric patients: comparisons between schizophrenia, bipolar disorder and depression. Mol. Psychiatry 21, 1696–1709 (2016).
pubmed: 26903267 pmcid: 6056174 doi: 10.1038/mp.2016.3
Frydecka, D. et al. Profiling inflammatory signatures of schizophrenia: a cross-sectional and meta-analysis study. Brain Behav. Immun. 71, 28–36 (2018).
pubmed: 29730395 doi: 10.1016/j.bbi.2018.05.002
Wang, A. K. & Miller, B. J. Meta-analysis of cerebrospinal fluid cytokine and tryptophan catabolite alterations in psychiatric patients: comparisons between schizophrenia, bipolar disorder, and depression. Schizophr. Bull. 44, 75–83 (2018).
pubmed: 28338954 doi: 10.1093/schbul/sbx035
Volk, D. W. Role of microglia disturbances and immune-related marker abnormalities in cortical circuitry dysfunction in schizophrenia. Neurobiol. Dis. 99, 58–65 (2017).
pubmed: 28007586 doi: 10.1016/j.nbd.2016.12.019
Fillman, S. G. et al. Elevated peripheral cytokines characterize a subgroup of people with schizophrenia displaying poor verbal fluency and reduced Broca’s area volume. Mol. Psychiatry 21, 1090–1098 (2016).
pubmed: 26194183 doi: 10.1038/mp.2015.90
Boerrigter, D. et al. Using blood cytokine measures to define high inflammatory biotype of schizophrenia and schizoaffective disorder. J. Neuroinflammation 14, 188 (2017).
pubmed: 28923068 pmcid: 5604300 doi: 10.1186/s12974-017-0962-y
Monji, A., Kato, T. & Kanba, S. Cytokines and schizophrenia: microglia hypothesis of schizophrenia. Psychiatry Clin. Neurosci. 63, 257–265 (2009).
pubmed: 19579286 doi: 10.1111/j.1440-1819.2009.01945.x
Smith, R. S. A comprehensive macrophage-T-lymphocyte theory of schizophrenia. Med. Hypotheses 39, 248–257 (1992).
pubmed: 1361959 doi: 10.1016/0306-9877(92)90117-U
Guilarte, T. R. TSPO in diverse CNS pathologies and psychiatric disease: a critical review and a way forward. Pharmacol. Ther. 194, 44–58 (2019).
pubmed: 30189290 doi: 10.1016/j.pharmthera.2018.09.003
Notter, T., Coughlin, J. M., Sawa, A. & Meyer, U. Reconceptualization of translocator protein as a biomarker of neuroinflammation in psychiatry. Mol. Psychiatry 23, 36–47 (2018).
pubmed: 29203847 doi: 10.1038/mp.2017.232
Plavén-Sigray, P. et al. Positron emission tomography studies of the glial cell marker translocator protein in patients with psychosis: a meta-analysis using individual participant data. Biol. Psychiatry 84, 433–442 (2018).
pubmed: 29653835 doi: 10.1016/j.biopsych.2018.02.1171 pmcid: 7893597
Marques, T. R. et al. Neuroinflammation in schizophrenia: meta-analysis of in vivo microglial imaging studies. Psychol. Med. 49, 2186–2196 (2019).
pubmed: 30355368 doi: 10.1017/S0033291718003057
Imaizumi, M. et al. Brain and whole-body imaging in nonhuman primates of [11 C]PBR28, a promising PET radioligand for peripheral benzodiazepine receptors. Neuroimage 39, 1289–1298 (2008).
pubmed: 18024084 doi: 10.1016/j.neuroimage.2007.09.063
Li, F. et al. Translocator protein 18 kDa (TSPO): an old protein with new functions? Biochemistry 55, 2821–2831 (2016).
pubmed: 27074410 doi: 10.1021/acs.biochem.6b00142
Gandal, M. J. et al. Transcriptome-wide isoform-level dysregulation in ASD, schizophrenia, and bipolar disorder. Science 362, eaat8127 (2018).
pubmed: 30545856 pmcid: 6443102 doi: 10.1126/science.aat8127
Notter, T. et al. Translational evaluation of translocator protein as a marker of neuroinflammation in schizophrenia. Mol. Psychiatry 23, 323–334 (2018).
pubmed: 28093569 doi: 10.1038/mp.2016.248
Mäntylä, T. et al. Altered activation of innate immunity associates with white matter volume and diffusion in first-episode psychosis. PLoS ONE 10, e0125112 (2015).
pubmed: 25970596 pmcid: 4430522 doi: 10.1371/journal.pone.0125112
Kori-Lindner, C. World medical association declaration of Helsinki. JAMA 310, 2191 (2013).
doi: 10.1001/jama.2013.281053
Larsson, A. et al. The effects of age and gender on plasma levels of 63 cytokines. J. Immunol. Methods 425, 58–61 (2015).
pubmed: 26080062 doi: 10.1016/j.jim.2015.06.009
Unamuno, X. et al. Adipokine dysregulation and adipose tissue inflammation in human obesity. Eur. J. Clin. Invest. 48, e12997 (2018).
pubmed: 29995306 doi: 10.1111/eci.12997
Shiels, M. S. et al. Cigarette smoking and variations in systemic immune and inflammation markers. J. Natl. Cancer Inst. 106, 1–8 (2014).
doi: 10.1093/jnci/dju294
Karoly, H. C., Bidwell, L. C., Mueller, R. L. & Hutchison, K. E. Investigating the relationships between alcohol consumption, cannabis use, and circulating cytokines: a preliminary analysis. Alcohol Clin. Exp. Res 42, 531–539 (2018).
pubmed: 29286537 pmcid: 5832595 doi: 10.1111/acer.13592
Hardikar, S. et al. Intraindividual variability over time in plasma biomarkers of inflammation and effects of long-term storage. Cancer Causes Control 25, 969–976 (2014).
pubmed: 24839050 pmcid: 4169209 doi: 10.1007/s10552-014-0396-0
Mantere, O. et al. Immunomodulatory effects of antipsychotic treatment on gene expression in first-episode psychosis. J. Psychiatr. Res. 109, 18–26 (2019).
pubmed: 30463035 doi: 10.1016/j.jpsychires.2018.11.008
Andreasen, N. C. The scale for the assessment of negative symptoms (SANS): conceptual and theoretical foundations. Br. J. Psychiatry Suppl. 155, 49–58 (1989).
doi: 10.1192/S0007125000291496
Ventura J. et al. Brief psychiatric rating scale expanded version 4.0: scales anchor points and administration manual (1993).
Kay, S. R., Fiszbein, A. & Opler, L. A. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr. Bull. 13, 261–276 (1987).
pubmed: 3616518 doi: 10.1093/schbul/13.2.261
Andreasen, N. C. et al. Remission in schizophrenia: proposed criteria and rationale for consensus. Am. J. Psychiatry 162, 441–449 (2005).
pubmed: 15741458 doi: 10.1176/appi.ajp.162.3.441
American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th ed (American Psychiatric Association, Washington, DC, 1994).
Hillmer, A. T. et al. Microglial depletion and activation: a [11C]PBR28 PET study in nonhuman primates. EJNMMI Res 7, 4–8 (2017).
doi: 10.1186/s13550-017-0305-0
Yoder, K. K. et al. Influence of TSPO Genotype on 11C-PBR28 Standardized Uptake Values. J. Nucl. Med. 54, 1320–1322 (2013).
pubmed: 23785173 doi: 10.2967/jnumed.112.118885
Kreisl, W. C. et al. A genetic polymorphism for translocator protein 18 Kda affects both in vitro and in vivo radioligand binding in human brain to this putative biomarker of neuroinflammation. J. Cereb. Blood Flow. Metab. 33, 53–58 (2013).
pubmed: 22968319 doi: 10.1038/jcbfm.2012.131
Fujita, M. et al. Kinetic analysis in healthy humans of a novel positron emission tomography radioligand to image the peripheral benzodiazepine receptor, a potential biomarker for inflammation. Neuroimage 40, 43–52 (2008).
pubmed: 18093844 doi: 10.1016/j.neuroimage.2007.11.011
Collste, K. et al. Test–retest reproducibility of [11C]PBR28 binding to TSPO in healthy control subjects. Eur. J. Nucl. Med Mol. Imaging 43, 173–183 (2016).
pubmed: 26293827 doi: 10.1007/s00259-015-3149-8
Tuisku, J. et al. Effects of age, BMI and sex on the glial cell marker TSPO — a multicentre [11C]PBR28 HRRT PET study. Eur. J. Nucl. Med Mol. Imaging 46, 2329–2338 (2019).
pubmed: 31363804 pmcid: 6717599 doi: 10.1007/s00259-019-04403-7
Frank E. Harrell, Jr. Hmisc: Harrell Miscellaneous. R package version 4.2-0 (2019) https://cran.r-project.org/package=Hmisc .
R Core Team. R: a language and environment for statistical computing. (2013) http://www.r-project.org/ .
Csardi, G. & Nepusz, T. The igraph software package for complex network research. InterJournal Complex Syst. 1695, 1–9 (2006).
Shannon, P. Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res. 13, 2498–2504 (2003).
pubmed: 14597658 pmcid: 403769 doi: 10.1101/gr.1239303
Gustavsen, J. A., Pai, S., Isserlin, R., Demchak, B. & Pico, A. R. RCy3: network biology using cytoscape from within R. F1000Research 8, 1774 (2019).
pubmed: 31819800 pmcid: 6880260 doi: 10.12688/f1000research.20887.2
Yoshie, O. & Matsushima, K. CCR4 and its ligands: from bench to bedside. Int Immunol. 27, 11–20 (2015).
pubmed: 25087232 doi: 10.1093/intimm/dxu079
Mantovani, A., Gray, P. A., Van Damme, J. & Sozzani, S. Macrophage-derived chemokine (MDC). J. Leukoc. Biol. 68, 400–404 (2000).
pubmed: 10985257
Vulcano, M. et al. Dendritic cells as a major source of macrophage-derived chemokine/CCL22 in vitro and in vivo. Eur. J. Immunol. 31, 812–822 (2001).
pubmed: 11241286 doi: 10.1002/1521-4141(200103)31:3<812::AID-IMMU812>3.0.CO;2-L
Nomiyama, H., Osada, N. & Yoshie, O. Systematic classification of vertebrate chemokines based on conserved synteny and evolutionary history. Genes Cells 18, 1–16 (2013).
pubmed: 23145839 doi: 10.1111/gtc.12013
Rapp, M. et al. CCL22 controls immunity by promoting regulatory T cell communication with dendritic cells in lymph nodes. J. Exp. Med. 216, 1170–1181 (2019).
pubmed: 30910796 pmcid: 6504218 doi: 10.1084/jem.20170277
Jenkins, M. K. et al. In vivo activation of antigen-specific CD4 T cells. Annu. Rev. Immunol. 19, 23–45 (2001).
pubmed: 11244029 doi: 10.1146/annurev.immunol.19.1.23
Perros, F., Hoogsteden, H. C., Coyle, A. J., Lambrecht, B. N. & Hammad, H. Blockade of CCR4 in a humanized model of asthma reveals a critical role for DC-derived CCL17 and CCL22 in attracting Th2 cells and inducing airway inflammation. Allergy 64, 995–1002 (2009).
pubmed: 19630858 doi: 10.1111/j.1398-9995.2009.02095.x
Zhang, Y., Fear, D. J., Willis-Owen, S. A. G., Cookson, W. O. & Moffatt, M. F. Global gene regulation during activation of immunoglobulin class switching in human B cells. Sci. Rep. 6, 37988 (2016).
pubmed: 27897229 pmcid: 5126563 doi: 10.1038/srep37988
Bischoff, L. et al. Cellular mechanisms of CCL22-mediated attenuation of autoimmune diabetes. J. Immunol. 194, 3054–3064 (2015).
pubmed: 25740943 doi: 10.4049/jimmunol.1400567
Eby, J. M. et al. CCL22 to activate Treg migration and suppress depigmentation in vitiligo. J. Invest. Dermatol. 135, 1574–1580 (2015).
pubmed: 25634358 pmcid: 5044299 doi: 10.1038/jid.2015.26
Ushio, A. et al. CCL22-producing resident macrophages enhance T cell response in Sjögren’s syndrome. Front Immunol. 9, 1–15 (2018).
doi: 10.3389/fimmu.2018.02594
Molineros, J. E. et al. Confirmation of five novel susceptibility loci for Systemic Lupus Erythematosus (SLE) and integrated network analysis of 82 SLE susceptibility loci. Hum. Mol. Genet. 26, ddx026 (2017).
doi: 10.1093/hmg/ddx026
Rump, L., Mattey, D. L., Kehoe, O. & Middleton, J. An initial investigation into endothelial CC chemokine expression in the human rheumatoid synovium. Cytokine 97, 133–140 (2017).
pubmed: 28648867 pmcid: 5516773 doi: 10.1016/j.cyto.2017.05.023
Fujii, H., Shimada, Y., Hasegawa, M., Takehara, K. & Sato, S. Serum levels of a Th1 chemoattractant IP-10 and Th2 chemoattractants, TARC and MDC, are elevated in patients with systemic sclerosis. J. Dermatol. Sci. 35, 43–51 (2004).
pubmed: 15194146 doi: 10.1016/j.jdermsci.2004.03.001
Anz, D. et al. Suppression of intratumoral CCL22 by type I interferon inhibits migration of regulatory T cells and blocks cancer progression. Cancer Res. 75, 4483–4493 (2015).
pubmed: 26432403 doi: 10.1158/0008-5472.CAN-14-3499
Yeung, O. W. H. et al. Alternatively activated (M2) macrophages promote tumour growth and invasiveness in hepatocellular carcinoma. J. Hepatol. 62, 607–616 (2015).
pubmed: 25450711 doi: 10.1016/j.jhep.2014.10.029
Klarquist, J. et al. Ccl22 diverts T regulatory cells and controls the growth of melanoma. Cancer Res. 76, 6230–6240 (2016).
pubmed: 27634754 pmcid: 5242486 doi: 10.1158/0008-5472.CAN-16-0618
Wei, Y. et al. C-C motif chemokine 22 ligand (CCL22) concentrations in sera of gastric cancer patients are related to peritoneal metastasis and predict recurrence within one year after radical gastrectomy. J. Surg. Res. 211, 266–278 (2017).
pubmed: 28501127 doi: 10.1016/j.jss.2016.11.067
Dimitrov, D. H. et al. Differential correlations between inflammatory cytokines and psychopathology in veterans with schizophrenia: Potential role for IL-17 pathway. Schizophr. Res. 151, 29–35 (2013).
pubmed: 24210870 doi: 10.1016/j.schres.2013.10.019
Hong, S. et al. Abnormalities in chemokine levels in schizophrenia and their clinical correlates. Schizophr. Res. 181, 63–69 (2017).
pubmed: 27650194 doi: 10.1016/j.schres.2016.09.019
Malmqvist, A. et al. Increased peripheral levels of TARC/CCL17 in first episode psychosis patients. Schizophr. Res. 210, 221–227 (2019).
pubmed: 30612841 doi: 10.1016/j.schres.2018.12.033
Schwarz, E., Guest, P. C., Steiner, J., Bogerts, B. & Bahn, S. Identification of blood-based molecular signatures for prediction of response and relapse in schizophrenia patients. Transl. Psychiatry 2, e82–e82 (2012).
pubmed: 22832819 pmcid: 3309553 doi: 10.1038/tp.2012.3
Perkins, D. O. et al. Towards a psychosis risk blood diagnostic for persons experiencing high-risk symptoms: preliminary results from the NAPLS project. Schizophr. Bull. 41, 419–428 (2015).
pubmed: 25103207 doi: 10.1093/schbul/sbu099
Bocchio-Chiavetto, L. et al. Immune and metabolic alterations in first episode psychosis (FEP) patients. Brain Behav. Immun. 70, 315–324 (2018).
pubmed: 29548996 doi: 10.1016/j.bbi.2018.03.013
Coughlin, J. M. et al. In vivo markers of inflammatory response in recent-onset schizophrenia: a combined study using [11C]DPA-713 PET and analysis of CSF and plasma. Transl. Psychiatry 6, e777–e777 (2016).
pubmed: 27070405 pmcid: 4872398 doi: 10.1038/tp.2016.40
Roos, P. et al. Inflammatory markers of CHMP2B-mediated frontotemporal dementia. J. Neuroimmunol. 324, 136–142 (2018).
pubmed: 30193769 doi: 10.1016/j.jneuroim.2018.08.009
AL-Ayadhi, L. Y. & Mostafa, G. A. Elevated serum levels of macrophage-derived chemokine and thymus and activation-regulated chemokine in autistic children. J. Neuroinflammation 10, 846 (2013).
doi: 10.1186/1742-2094-10-72
Milenkovic, V. M. et al. Macrophage-derived chemokine: a putative marker of pharmacological therapy response in major depression? Neuroimmunomodulation 24, 106–112 (2017).
pubmed: 28898872 doi: 10.1159/000479739
Scheu, S., Ali, S., Ruland, C., Arolt, V. & Alferink, J. The C-C chemokines CCL17 and CCL22 and their receptor CCR4 in CNS autoimmunity. Int J. Mol. Sci. 18, 2306 (2017).
pmcid: 5713275 doi: 10.3390/ijms18112306
Peferoen, L. A. N. et al. Activation status of human microglia is dependent on lesion formation stage and remyelination in multiple sclerosis. J. Neuropathol. Exp. Neurol. 74, 48–63 (2015).
pubmed: 25470347 doi: 10.1097/NEN.0000000000000149
Håkansson, I. et al. Neurofilament levels, disease activity and brain volume during follow-up in multiple sclerosis. J. Neuroinflammation 15, 209 (2018).
pubmed: 30021640 pmcid: 6052680 doi: 10.1186/s12974-018-1249-7
Forde, E. A., Dogan, R.-N. E. & Karpus, W. J. CCR4 contributes to the pathogenesis of experimental autoimmune encephalomyelitis by regulating inflammatory macrophage function. J. Neuroimmunol. 236, 17–26 (2011).
pubmed: 21575994 pmcid: 3139027 doi: 10.1016/j.jneuroim.2011.04.008
Poppensieker, K. et al. CC chemokine receptor 4 is required for experimental autoimmune encephalomyelitis by regulating GM-CSF and IL-23 production in dendritic cells. Proc. Natl. Acad. Sci. USA 109, 3897–3902 (2012).
pubmed: 22355103 doi: 10.1073/pnas.1114153109 pmcid: 3309768
Jordão, M. J. C. et al. Single-cell profiling identifies myeloid cell subsets with distinct fates during neuroinflammation. Science 363, eaat7554 (2019).
pubmed: 30679343 doi: 10.1126/science.aat7554
Ambrée, O. et al. Reduced locomotor activity and exploratory behavior in CC chemokine receptor 4 deficient mice. Behav. Brain Res 314, 87–95 (2016).
pubmed: 27469058 doi: 10.1016/j.bbr.2016.07.041
Fülle, L. et al. CCL17 exerts a neuroimmune modulatory function and is expressed in hippocampal neurons. Glia 66, 2246–2261 (2018).
pubmed: 30277599 doi: 10.1002/glia.23507
Mogensen, T. H. Pathogen recognition and inflammatory signaling in innate immune defenses. Clin. Microbiol Rev. 22, 240–273 (2009).
pubmed: 19366914 pmcid: 2668232 doi: 10.1128/CMR.00046-08
Gardner, R. M., Dalman, C., Wicks, S., Lee, B. K. & Karlsson, H. Neonatal levels of acute phase proteins and later risk of non-affective psychosis. Transl. Psychiatry 3, e228–e228 (2013).
pubmed: 23423137 pmcid: 3591005 doi: 10.1038/tp.2013.5
Upthegrove, R., Manzanares-Teson, N. & Barnes, N. M. Cytokine function in medication-naive first episode psychosis: a systematic review and meta-analysis. Schizophr. Res. 155, 101–108 (2014).
pubmed: 24704219 doi: 10.1016/j.schres.2014.03.005
Miller, B. J., Buckley, P., Seabolt, W., Mellor, A. & Kirkpatrick, B. Meta-analysis of cytokine alterations in schizophrenia: clinical status and antipsychotic effects. Biol. Psychiatry 70, 663–671 (2011).
pubmed: 21641581 pmcid: 4071300 doi: 10.1016/j.biopsych.2011.04.013
Lindgren, M. et al. Childhood adversities and clinical symptomatology in first-episode psychosis. Psychiatry Res. 258, 374–381 (2017).
pubmed: 28867407 doi: 10.1016/j.psychres.2017.08.070
Kalk, N. J. et al. Are prescribed benzodiazepines likely to affect the availability of the 18 kDa translocator protein (TSPO) in PET studies? Synapse 67, 909–912 (2013).
pubmed: 23666806 doi: 10.1002/syn.21681
Collste, K. et al. Lower levels of the glial cell marker TSPO in drug-naive first-episode psychosis patients as measured using PET and [11C]PBR28. Mol. Psychiatry 22, 850–856 (2017).
pubmed: 28194003 doi: 10.1038/mp.2016.247
Bloomfield, P. S. et al. The effects of haloperidol on microglial morphology and translocator protein levels: an in vivo study in rats using an automated cell evaluation pipeline. J. Psychopharmacol. 32, 1264–1272 (2018).
pubmed: 30126329 doi: 10.1177/0269881118788830
Venneti, S., Lopresti, B. J. & Wiley, C. A. The peripheral benzodiazepine receptor (Translocator protein 18kDa) in microglia: From pathology to imaging. Prog. Neurobiol. 80, 308–322 (2006).
pubmed: 17156911 pmcid: 1849976 doi: 10.1016/j.pneurobio.2006.10.002
Betlazar, C., Harrison-Brown, M., Middleton, R., Banati, R. & Liu, G.-J. Cellular sources and regional variations in the expression of the neuroinflammatory marker translocator protein (TSPO) in the normal brain. Int J. Mol. Sci. 19, 2707 (2018).
pmcid: 6163555 doi: 10.3390/ijms19092707
Cosenza-Nashat, M. et al. Expression of the translocator protein of 18 kDa by microglia, macrophages and astrocytes based on immunohistochemical localization in abnormal human brain. Neuropathol. Appl. Neurobiol. 35, 306–328 (2009).
pubmed: 19077109 doi: 10.1111/j.1365-2990.2008.01006.x
Bahney, J. & von Bartheld, C. S. The cellular composition and glia–neuron ratio in the spinal cord of a human and a nonhuman primate: comparison with other species and brain regions. Anat. Rec. 301, 697–710 (2018).
doi: 10.1002/ar.23728
Veronese, M. et al. Kinetic modelling of [11 C]PBR28 for 18 kDa translocator protein PET data: a validation study of vascular modelling in the brain using XBD173 and tissue analysis. J. Cereb. Blood Flow. Metab. 38, 1227–1242 (2018).
pubmed: 28580888 doi: 10.1177/0271678X17712388
Pannell, M. et al. Imaging of translocator protein upregulation is selective for pro-inflammatory polarized astrocytes and microglia. Glia 68, 280–297 (2019).
pubmed: 31479168 pmcid: 6916298 doi: 10.1002/glia.23716
Bae, K. R., Shim, H. J., Balu, D., Kim, S. R. & Yu, S. W. Translocator protein 18 kDa negatively regulates inflammation in microglia. J. Neuroimmune Pharmacol. 9, 424–437 (2014).
pubmed: 24687172 doi: 10.1007/s11481-014-9540-6
Erny, D. et al. Host microbiota constantly control maturation and function of microglia in the CNS. Nat. Neurosci. 18, 965–977 (2015).
pubmed: 26030851 pmcid: 5528863 doi: 10.1038/nn.4030
Baufeld, C., Osterloh, A., Prokop, S., Miller, K. R. & Heppner, F. L. High-fat diet-induced brain region-specific phenotypic spectrum of CNS resident microglia. Acta Neuropathol. 132, 361–375 (2016).
pubmed: 27393312 pmcid: 4992033 doi: 10.1007/s00401-016-1595-4

Auteurs

Heikki Laurikainen (H)

Turku PET Centre, University of Turku, Turku, Finland. heikki.laurikainen@utu.fi.
Department of Psychiatry, University of Turku and Turku University Hospital, Turku, Finland. heikki.laurikainen@utu.fi.

Arja Vuorela (A)

Clinicum, University of Helsinki, Helsinki, Finland.

Anna Toivonen (A)

Department of Psychiatry, University of Turku and Turku University Hospital, Turku, Finland.

Linnea Reinert-Hartwall (L)

Research Program for Clinical and Molecular Metabolism, University of Helsinki, Helsinki, Finland.

Kalevi Trontti (K)

SleepWell Research Program, University of Helsinki, Helsinki, Finland.
Department of Psychology and Logopedics, University of Helsinki, Helsinki, Finland.

Maija Lindgren (M)

Finnish Institute for Health and Welfare, Mental Health Unit, Helsinki, Finland.

Jaakko Keinänen (J)

Finnish Institute for Health and Welfare, Mental Health Unit, Helsinki, Finland.

Teemu Mäntylä (T)

Department of Psychology and Logopedics, University of Helsinki, Helsinki, Finland.
Finnish Institute for Health and Welfare, Mental Health Unit, Helsinki, Finland.

Janina Paju (J)

Department of Psychiatry, University of Turku and Turku University Hospital, Turku, Finland.

Tuula Ilonen (T)

Department of Psychiatry, University of Turku and Turku University Hospital, Turku, Finland.

Reetta-Liina Armio (RL)

Turku PET Centre, University of Turku, Turku, Finland.
Department of Psychiatry, University of Turku and Turku University Hospital, Turku, Finland.

Maija Walta (M)

Department of Psychiatry, University of Turku and Turku University Hospital, Turku, Finland.

Jouni Tuisku (J)

Turku PET Centre, University of Turku, Turku, Finland.

Semi Helin (S)

Turku PET Centre, University of Turku, Turku, Finland.

Päivi Marjamäki (P)

Turku PET Centre, University of Turku, Turku, Finland.

Iiris Hovatta (I)

SleepWell Research Program, University of Helsinki, Helsinki, Finland.
Department of Psychology and Logopedics, University of Helsinki, Helsinki, Finland.
ORCID: 0000-0002-5990-7892

Sebastian Therman (S)

Finnish Institute for Health and Welfare, Mental Health Unit, Helsinki, Finland.
ORCID: 0000-0001-9407-4905

Outi Vaarala (O)

Research Program for Clinical and Molecular Metabolism, University of Helsinki, Helsinki, Finland.

Outi Linnaranta (O)

Douglas Mental Health University Institute, Montreal, QC, Canada.
Department of Psychiatry, McGill University, Montreal, QC, Canada.
ORCID: 0000-0002-0383-7215

Tuula Kieseppä (T)

Department of Psychiatry, Helsinki University and Helsinki University Hospital, Helsinki, Finland.

Raimo K R Salokangas (RKR)

Department of Psychiatry, University of Turku and Turku University Hospital, Turku, Finland.

Jarno Honkanen (J)

Research Program for Clinical and Molecular Metabolism, University of Helsinki, Helsinki, Finland.

Jarmo Hietala (J)

Turku PET Centre, University of Turku, Turku, Finland.
Department of Psychiatry, University of Turku and Turku University Hospital, Turku, Finland.

Jaana Suvisaari (J)

Finnish Institute for Health and Welfare, Mental Health Unit, Helsinki, Finland.
ORCID: 0000-0001-7167-0990

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Système nerveux › Système nerveux central › Encéphale › Elevated serum chemokine CCL22 levels in...
questionsmedicales.fr › Facteurs biologiques › Protéines et peptides de signalisation intercellulaire › Cytokines › Chimiokines › Chimiokines CC › Chimiokine CCL22 › Elevated serum chemokine CCL22 levels in...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Elevated serum chemokine CCL22 levels in...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Caractéristiques des études épidémiologiques › Études épidémiologiques › Études de cohortes › Études longitudinales › Elevated serum chemokine CCL22 levels in...
questionsmedicales.fr › Cellules › Névroglie › Elevated serum chemokine CCL22 levels in...
questionsmedicales.fr › Troubles mentaux › Schizophrénie et troubles avec traits psychotiques › Troubles psychotiques › Elevated serum chemokine CCL22 levels in...